Renaissance Technologies LLC Acquires New Stake in CollPlant Biotechnologies Ltd. (NASDAQ:CLGN)

Renaissance Technologies LLC bought a new position in CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 10,600 shares of the company’s stock, valued at approximately $38,000. Renaissance Technologies LLC owned about 0.09% of CollPlant Biotechnologies as of its most recent filing with the Securities and Exchange Commission (SEC).

Separately, Wells Fargo & Company MN lifted its stake in shares of CollPlant Biotechnologies by 110.1% in the 4th quarter. Wells Fargo & Company MN now owns 8,405 shares of the company’s stock worth $30,000 after purchasing an additional 4,405 shares during the period. 21.69% of the stock is currently owned by institutional investors.

CollPlant Biotechnologies Stock Performance

NASDAQ:CLGN opened at $1.82 on Friday. The stock has a 50-day simple moving average of $2.60 and a two-hundred day simple moving average of $3.43. The firm has a market capitalization of $20.85 million, a PE ratio of -1.18 and a beta of 1.24. CollPlant Biotechnologies Ltd. has a 52-week low of $1.81 and a 52-week high of $6.75.

CollPlant Biotechnologies (NASDAQ:CLGN) last announced its quarterly earnings data on Wednesday, March 26th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.08. CollPlant Biotechnologies had a negative return on equity of 77.05% and a negative net margin of 2,680.00%. The company had revenue of $0.17 million during the quarter, compared to the consensus estimate of $0.36 million. Equities analysts forecast that CollPlant Biotechnologies Ltd. will post -1.44 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, D. Boral Capital restated a “buy” rating and set a $14.00 target price on shares of CollPlant Biotechnologies in a research report on Thursday, March 27th.

CollPlant Biotechnologies Profile

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.